Skip to content

Jazz Pharmaceuticals JAZZ Licensing Arrangements

Licensing Arrangements at other companies

Incyte logo
IncyteINCY

Other financials

Income statement

See full
Revenue$1.1B+19.1%
Operating income$336.6M+702%
Net income$293.1M+417%
EPS (diluted)$4.43+391%

Balance sheet

See full
Cash & equivalents$667.5M-64.1%
Total debt$5.4B-0.1%
Total equity$4.5B+8.6%
Total assets$11.9B+2.8%

Cash flow

See full
Operating cash flow$408.2M-5.0%
CapEx$19.7M+41.7%
Free cash flow$388.5M-6.6%

Valuation

See full
Market cap$14.11B+54.4%
Enterprise value$18.85B+47.7%
P/S3.2×+0.9×

Profitability

See full
Operating margin-11.9%-28.1pp
Net margin-8.9%-20.5pp
FCF margin28.6%-8.6pp

Returns & leverage

See full
Return on equity-9.1%-21.2pp
Debt / equity1.2×-0.1×
Current ratio-1.3×

Where this comes from

Reported directly by Jazz Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:AccruedRoyaltiesCurrent.

The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Jazz Pharmaceuticals's licensing arrangements.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Jazz Pharmaceuticals's licensing arrangements?
Jazz Pharmaceuticals (JAZZ) reported licensing arrangements of $47.6M in Q1 2026.
How has Jazz Pharmaceuticals's licensing arrangements changed year-over-year?
Jazz Pharmaceuticals's licensing arrangements increased by 62.6% year-over-year, from $29.27M to $47.6M.
What is the long-term trend for Jazz Pharmaceuticals's licensing arrangements?
Over 5 years (2020 to 2025), Jazz Pharmaceuticals's licensing arrangements has grown at a 25.3% compound annual growth rate (CAGR), from $15.23M to $47.1M.